Reed Jobs would rather talk about curing cancer than his last name
When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was still reeling from its post-pandemic crash. Now, the venture outfit has a team of 17; a cluster of blockbuster drugs are all losing patent protection in roughly the same window, creating all kinds of new opportunities; and AI has gone from a curiosity to, in Jobs's words, a huge part of what Yosemite does. "I didn't expect Yosemite to be moving this fast," he said.
حوّل المعلومة إلى قرار بياناتي داخل ستارت أب كيت برو
أدوات تحليل مالية ونماذج تقييم جاهزة — مجانًا للمؤسّسين العرب.
أخبار ذات صلة
50 rising AI startups in Asia
These AI startups have a shot at becoming the next big thing.
14 يوليو 2026X just tweaked its algorithm to make it more friendly, less battleground
The social media site says it will amplify posts made by users' mutual followers' to give the feed more of a communal feel.
13 يوليو 2026Chinese AI chip startup Oriental Compute Core debuts DF1000
DF1000 chip uses DRAM-logic wafer-level hybrid-bonded 3D packaging for higher bandwidth.
13 يوليو 2026Conor McGregor and WeWork Made the Exact Same Mistake. Here’s How to Tell If Your Startup Is Making It Too
Success can hide structural weaknesses. Ambitious moves can reveal it.
13 يوليو 2026